ABIOMED, Inc. (ABMD) Shares Bought by Tirschwell & Loewy Inc.
Tirschwell & Loewy Inc. boosted its position in ABIOMED, Inc. (NASDAQ:ABMD) by 0.4% during the second quarter, Holdings Channel reports. The institutional investor owned 81,030 shares of the medical equipment provider’s stock after buying an additional 325 shares during the period. ABIOMED accounts for about 1.8% of Tirschwell & Loewy Inc.’s holdings, making the stock its 26th largest position. Tirschwell & Loewy Inc.’s holdings in ABIOMED were worth $11,612,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of ABMD. Shaker Investments LLC OH purchased a new stake in ABIOMED during the first quarter worth approximately $2,198,000. Great West Life Assurance Co. Can increased its stake in ABIOMED by 4.9% in the first quarter. Great West Life Assurance Co. Can now owns 23,951 shares of the medical equipment provider’s stock worth $2,997,000 after buying an additional 1,126 shares in the last quarter. Jennison Associates LLC purchased a new stake in ABIOMED during the first quarter worth approximately $12,939,000. Oregon Public Employees Retirement Fund increased its stake in ABIOMED by 1.4% in the first quarter. Oregon Public Employees Retirement Fund now owns 14,038 shares of the medical equipment provider’s stock worth $1,758,000 after buying an additional 200 shares in the last quarter. Finally, Profund Advisors LLC increased its stake in ABIOMED by 6.7% in the first quarter. Profund Advisors LLC now owns 6,356 shares of the medical equipment provider’s stock worth $796,000 after buying an additional 398 shares in the last quarter. Institutional investors own 91.09% of the company’s stock.
Shares of ABIOMED, Inc. (ABMD) opened at 151.37 on Monday. The stock has a market capitalization of $6.64 billion, a P/E ratio of 88.52 and a beta of 0.20. The firm’s 50-day moving average price is $145.53 and its 200-day moving average price is $130.74. ABIOMED, Inc. has a 12 month low of $95.14 and a 12 month high of $157.41.
ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.03. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The business had revenue of $132.47 million for the quarter, compared to analyst estimates of $130.83 million. During the same period last year, the company posted $0.29 EPS. The business’s revenue was up 28.6% on a year-over-year basis. On average, equities research analysts forecast that ABIOMED, Inc. will post $2.24 EPS for the current year.
A number of equities research analysts have issued reports on the company. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Jefferies Group LLC upped their price objective on ABIOMED from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Piper Jaffray Companies restated an “overweight” rating and set a $160.00 price objective (up from $145.00) on shares of ABIOMED in a research report on Thursday, July 27th. Finally, William Blair restated an “outperform” rating on shares of ABIOMED in a research report on Thursday, June 8th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $158.29.
In other news, VP Michael G. Howley sold 18,279 shares of ABIOMED stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $133.56, for a total transaction of $2,441,343.24. Following the sale, the vice president now owns 62,105 shares of the company’s stock, valued at approximately $8,294,743.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO David M. Weber sold 16,500 shares of ABIOMED stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the sale, the chief operating officer now directly owns 125,122 shares in the company, valued at approximately $18,471,760.86. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.